HORUS PHARMA SAS

Their core work

Horus Pharma is a French ophthalmic pharmaceutical SME focused on dry eye disease and ocular surface conditions. They work on both the diagnostic and therapeutic sides of this space: in 2014–2015 they led clinical validation of a point-of-care medical device for eye diagnostics, and by 2018 they were embedded as an industry partner in a large EU-funded PhD training network for dry eye drug development. For pharmaceutical companies and research consortia, they bring real-world industry context — formulation know-how, drug discovery experience, and clinical validation capability — all within a tightly defined ophthalmology niche.

What they specialise in

How they've shifted over time

In their first H2020 project (2014–2015), Horus Pharma focused on the diagnostic device side of ophthalmology — building and validating a point-of-care tool for clinical monitoring. By their second project (2018–2022), the emphasis had clearly shifted toward the pharmaceutical pipeline: drug discovery, medicinal chemistry, and formulation science. The core disease area — dry eye and ocular surface — remained constant, but the company moved from device validation toward drug development, suggesting a deliberate strategic shift deeper into the therapeutic space.

Horus Pharma appears to be deepening its pharmaceutical R&D capabilities in the dry eye space, making them an increasingly relevant industry partner for academic drug development consortia targeting ocular surface diseases.

How they like to work

Horus Pharma has experience in both roles: as a solo coordinator on a small SME Instrument grant and as a third-party industry partner in a large MSCA Innovative Training Network. Their third-party status in IT-DED3 is typical for pharmaceutical SMEs in MSCA networks — they likely hosted PhD researchers or provided industrial training, rather than leading research tasks. With 17 unique partners across 8 countries from just 2 projects, their per-project network density is high, suggesting active engagement with diverse consortia rather than isolated participation.

Horus Pharma has connected with 17 unique partners across 8 countries, predominantly through the large IT-DED3 training network. Their geographic footprint is European, with no indication of partnerships outside the EU.

What sets them apart

Horus Pharma occupies a rare position as a small French pharma company with hands-on experience in both ophthalmic diagnostics and dry eye drug formulation — two areas that rarely overlap in a single SME. Their participation in an MSCA-ITN as an industry partner signals that academia trusts them as a real-world counterpart for training the next generation of dry eye researchers. For a consortium building a drug-device combination project in ophthalmology, they are the kind of focused industry player that adds credibility without competing for scientific leadership.

Highlights from their portfolio

• eyePoC
  Horus Pharma coordinated this SME Instrument Phase 1 grant — their only EU-funded leadership role — validating a point-of-care diagnostic device for ocular surface conditions, demonstrating early-stage commercial innovation capacity.
• IT-DED3
  Participation as an industry third party in this MSCA Innovative Training Network for dry eye drug development signals that Horus Pharma is recognized by the academic community as a credible pharmaceutical industry partner in this niche.